Talaris Therapeutics Performance
| TALSDelisted Stock | USD 2.98 0.10 3.25% |
The entity has a beta of 0.0046, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Talaris Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Talaris Therapeutics is expected to be smaller as well. Talaris Therapeutics right now has a risk of 0.0%. Please validate Talaris Therapeutics expected short fall, and the relationship between the maximum drawdown and rate of daily change , to decide if Talaris Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Talaris Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable essential indicators, Talaris Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 18.6 M |
Talaris |
Talaris Therapeutics Relative Risk vs. Return Landscape
If you would invest 298.00 in Talaris Therapeutics on September 19, 2024 and sell it today you would earn a total of 0.00 from holding Talaris Therapeutics or generate 0.0% return on investment over 90 days. Talaris Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Talaris, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Talaris Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Talaris Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Talaris Therapeutics, and traders can use it to determine the average amount a Talaris Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| TALS |
Based on monthly moving average Talaris Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Talaris Therapeutics by adding Talaris Therapeutics to a well-diversified portfolio.
Talaris Therapeutics Fundamentals Growth
Talaris Stock prices reflect investors' perceptions of the future prospects and financial health of Talaris Therapeutics, and Talaris Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Talaris Stock performance.
| Return On Equity | -0.42 | |||
| Return On Asset | -0.23 | |||
| Current Valuation | (28.92 M) | |||
| Shares Outstanding | 42.81 M | |||
| Price To Book | 0.28 X | |||
| EBITDA | (74.31 M) | |||
| Cash And Equivalents | 207.11 M | |||
| Cash Per Share | 4.97 X | |||
| Total Debt | 2.88 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 3.49 X | |||
| Cash Flow From Operations | (60.86 M) | |||
| Earnings Per Share | (1.97) X | |||
| Total Asset | 193.72 M | |||
| Retained Earnings | (164.74 M) | |||
About Talaris Therapeutics Performance
Assessing Talaris Therapeutics' fundamental ratios provides investors with valuable insights into Talaris Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Talaris Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky. Talaris Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 128 people.Things to note about Talaris Therapeutics performance evaluation
Checking the ongoing alerts about Talaris Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Talaris Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Talaris Therapeutics is not yet fully synchronised with the market data | |
| Talaris Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (73.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Talaris Therapeutics currently holds about 207.11 M in cash with (60.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 78.0% of the company shares are owned by institutional investors |
- Analyzing Talaris Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Talaris Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Talaris Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Talaris Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Talaris Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Talaris Therapeutics' stock. These opinions can provide insight into Talaris Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |